ASH 2020 | Combination of mosunetuzumab with CHOP in DLBCL
Tycel Phillips
• 14 Dec 2020
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, discusses the interim results of a Phase Ib/II study (NCT03677141) investigating the safety and efficacy of a novel combination of mosunetuzumab with CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The addition of mosunetuzumab to the standard CHOP regimen achieved an overall response rate (ORR) of 96%, with a complete response rate of 85% in patients with newly diagnosed DLBCL. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
